Announcement Regarding Updates to Patient Metrics Japan,
the Epidemiology Module of CancerMPact®
**Updates will be going live online on April 30, 2013**
REGISTRY SOURCES
We have included updated data for most of the registry sources used for incidence, staging and survival.
Treatment data was updated with the most recent Treatment Architecture survey (2012).
We have added new registry sources for staging:



Chiba
Shimane
Aomori
We added a new registry source for survival

Survival data by stage from the Member Hospitals of
o the Association of Clinical Cancer Centers This is national level, stage specific survival data that
just became available in November 2012.
o It includes patients diagnosed for years 2000 – 2004
o It provides annual survival rates for 1 – 5 yrs after diagnosis
o Uses AJCC staging
Once the new data is incorporated into Kantar Health’s proprietary models, we update forecasts based on
observed changes in historic trends.
NEW ADDITIONS
Several additional changes have been made to Patient Metrics in order to provide greater value to our clients.



Non-Small Cell Lung:
o NSCL is broken out by squamous, adenocarcinoma and other non-squamous.
o Maintenance therapy after first line drug therapy is now shown for 3 years (2010-2012).
Melanoma
o Staging for melanoma is now based on two recently published melanoma specific studies.
Previously, staging was based on registry data which included all skin cancers, not just
melanoma.
o This has resulted in a shift in the staging distribution to more advanced stages.
Non Hodgkin’s Lymphoma
o We have modified the types of NHL included in follicular and diffuse large B cell to be consistent
with current WHO recommendations. Marginal zone (ICD O3 9699) will be moved from follicular
to other indolent. Splenic marginal zone (ICD O3 9689) will be moved from DLBC to other
indolent. Mediastinal large B cell (ICD O3 9679) will be added to DLBC.
o While total NHL numbers will not change, follicular will be about 50% smaller, other indolent will
be correspondingly larger. DLBC change is minor.
1
April 2013
JAPAN UPDATES: HIGHLIGHTS OF CHANGES
The following tumors have experienced greater than a 10% change in Stage IV Active Disease as a result of
new incidence data, staging distributions, and/or survival data:








Bladder
Breast
Cervix
Head and Neck
Melanoma
Non Small Cell Lung
Prostate
Rectum
ADDITIONAL ASSISTANCE
If you have need for additional information or clarification regarding these changes, please feel free to contact
the following members of Kantar Health’s Cancer Epidemiology team:



David Robinson
Vice President
Tel: 314-529-3057
david.robinson@kantarhealth.com
Knar Nersesyan
Consultant
Tel: 314-529-3067
knar.nersesyan@kantarhealth.com
Julie Katz
Associate Consultant
Tel: 650-403-7005
julie.katz@kantarhealth.com
2
April 2013

Maya Kumar
Analyst
Tel: 650-403-7006
maya.kumar@kantarhealth.com
3
April 2013